RxDoctor Payments DataLook up a doctor →

Vodur Reddy, MD

Hematology & Oncology · Reno, NVNPI 1538109004

Payments from drug & device makers

$12,142in general payments, 2019–2025

Across 147 payments — averaging $82.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Exelixis Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$493
  • Novartis$365
  • Array Biopharma Inc$212
  • AstraZeneca$176
  • plus $2K from 40 others

What the payments were for

  • Consulting fees$4,49037%
  • Travel & lodging$8827%
  • Food & beverage$6,70455%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,142 in reported general payments places this provider in the 40th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada

Medicare billing

Part B allowed, 2024
$3,578,090
Medicare patients
756
Services billed
126,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide29$678,764
JakafiRuxolitinib Phosphate27$438,278
RevlimidLenalidomide29$426,493
BrukinsaZanubrutinib24$354,289
SprycelDasatinib11$187,404
CalquenceAcalabrutinib Maleate12$183,150
TasignaNilotinib Hcl12$118,725
EliquisApixaban76$58,268
XareltoRivaroxaban22$19,303
RetacritEpoetin Alfa-Epbx11$7,398
Anastrozole193$4,325
Hydroxyurea85$2,164
Acyclovir46$705
Letrozole15$494
Gabapentin38$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$493$866,16940 claims
Incyte CorporationJakafi$45$438,27827 claims
Bristol Myers SquibbRevlimid$60$426,49329 claims
Beigene USA, Inc.Brukinsa$156$354,28924 claims
AstraZenecaCalquence$176$183,15012 claims
NovartisTasigna$365$118,72512 claims
PfizerEliquis, Retacrit$116$65,66787 claims
Johnson & JohnsonXarelto$92$19,30322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 82 hematology & oncology providers in Nevada.

Other hematology & oncology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →